Breast Cancer

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

The FDA approved adjuvant ribociclib plus an aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

RLY-2608 plus fulvestrant generated clinically meaningful PFS outcomes in PI3Kα-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.